Makatussin Comp. is primarily used to provide supportive symptomatic assistance by addressing specific patterns of irritating cough and symptoms related to physical discomfort, often associated with acute or disruptive episodes. The benefit supports patients during difficult episodes by easing distress and supports general well-being during symptomatic phases.

This class of medication may be part of symptomatic management in clinical settings marked by the need to manage symptoms related to heightened physiological activity. It is commonly used across conditions presenting with acute episodes, such as the symptomatic cough associated with cold-like illness, post-infectious irritation, and situations requiring the easing of nocturnal coughing.

Therapeutic Focus: Managing Disruptive Cough

“Supportive relief may be helpful when symptoms lead to temporary functional strain, especially during periods of rest.”

This assistance is relevant in contexts marked by increased discomfort from throat or airway irritation. By easing symptoms that interfere with rest, the medication may contribute to improved comfort and helps maintain a sense of stability, supporting patients during difficult episodes by easing distress.

Regulatory References

1. NIH DailyMed Label for Antitussive/Expectorant Combinations

Who can and cannot use Makatussin Comp.?

The eligibility profile for Makatussin Comp. is strictly defined by regulatory authorities and centers on age, underlying health conditions, and physiological status. Use is generally allowed for adults who do not present any specific contraindications.

Populations Absolutely Contraindicated The medicine must not be used by children younger than 12 years of age due to the risk of severe respiratory depression from the Dihydrocodeine component. It is also contraindicated for breastfeeding women. Absolute non-eligibility applies to patients with significant respiratory depression, acute/severe bronchial asthma, and those taking Monoamine Oxidase Inhibitors (MAOIs) or who have taken them within the last 14 days. Individuals with known hypersensitivity to the active ingredients must also not use the medicine.

Restricted and Conditional Use Adolescents aged 12 to 18 with specific conditions like obstructive sleep apnea or severe lung disease are not recommended to use this medicine. Furthermore, eligibility is limited for patients with certain pre-existing conditions. These include narrow-angle glaucoma, symptomatic prostatic hypertrophy, pyloroduodenal obstruction, head injury, and liver or kidney disease, for which use requires careful consideration due to the risk of exacerbating the condition. Use during pregnancy is restricted to situations where it is clearly necessary. Older adults should also use the medicine with caution.

Interactions with other medicines and products

The interaction profile for Makatussin Comp. is established by regulatory authorities based on the combined action of its two components, Dihydrocodeine and Diphenhydramine.

Contraindicated and Pharmacodynamic Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited due to the dual risk of central nervous system excitation and intensified anticholinergic effects. The product exhibits significant additive depressant effects when taken concurrently with Central Nervous System (CNS) Depressants and Alcohol (Ethanol). This pharmacodynamic interaction may lead to severe sedation and respiratory depression. A further pharmacodynamic risk is documented with Serotonergic Agents (such as SSRIs and Triptans), which carry a risk of Serotonin Syndrome.

Metabolic and Exposure Alterations

The drug is subject to a formal pharmacokinetic interaction involving the Cytochrome P450 2D6 (CYP2D6) enzyme. Co-administration with CYP2D6 Inhibitors (including certain antidepressants and antifungals) causes a regulated outcome: it increases the plasma concentration of Dihydrocodeine (the parent drug) while concurrently decreasing the active metabolite Dihydromorphine.

Population-Specific Constraints

Official documentation notes that patients with Hepatic or Renal Impairment may experience slower clearance of the medicine. This reduced removal rate increases the potential for accumulation, which can heighten the severity of observed interactions.

Central Modulation of the Cough Reflex

This preparation’s central action is mediated by Dihydrocodeine, which functions as an agonist at central mu-opioid receptors. These receptors are concentrated within the brainstem’s cough center, the neural network responsible for regulating the cough reflex arc. The interaction at the mu-opioid receptor initiates a downstream mechanistic cascade that raises the central threshold required to trigger a cough, consequently altering the central signaling patterns of the reflex.

Antagonism of Histamine and Neural Pathway Modulation

The second component, Diphenhydramine, exerts its mechanism primarily through blocking the action of histamine at the H1 receptor. Diphenhydramine readily crosses the blood-brain barrier to modulate central neural activity. This H1 antagonism, coupled with an associated anticholinergic activity on muscarinic acetylcholine receptors, influences pathways that regulate vigilance and is associated with alterations in signaling patterns related to wakefulness and sleep cycles.

Makatussin Comp. is administered via the oral route as a liquid solution, consistent with its formulation as a cough linctus. The usage of this fixed-dose combination, which contains Dihydrocodeine and Diphenhydramine, is defined by guidelines for opioid-antitussive products, focusing on short-term management.

Administration and Schedule Principles

The dosing regimen is based on the lowest effective dose necessary for symptomatic relief. Administration is generally scheduled on an as-needed basis, typically allowing a dose to be repeated every four to six hours (q4–6h). Accurate measurement is a mandatory procedural step; the liquid must be dispensed using a calibrated milliliter measuring device to ensure precise intake, rather than a household spoon.

The total daily intake must adhere to a strict maximum, generally not to exceed four to six total doses in a 24-hour period, a constraint established to prevent accumulation and over-use. The medication may be administered with food or milk to help mitigate potential gastrointestinal upset, or otherwise taken independently of meals.

Duration and Population Rules

Guidelines mandate that the medication is intended for short-term use only, limiting the duration of treatment to the shortest period possible, often not exceeding five to seven days. This product is not intended for the management of chronic conditions. Due to the active ingredients, specific age groups have usage restrictions. The product is generally not recommended for pediatric patients under a certain age (e.g., 12 or 18 years, depending on regional authority). Special caution is required for older adults and patients with known hepatic or renal impairment, often necessitating a reduced dose or decreased frequency.

Makatussin Comp.: Recent Clinical Evidence

The formulation contains two active antitussive components: Codeine and Noscapine. Clinical research has primarily focused on the effectiveness and tolerability of these ingredients individually or as a class of cough suppressants, rather than the specific combination found in this product.

---

Efficacy in Cough Suppression

Studies have explored whether the active components of this drug are associated with a reduction in cough frequency and intensity, particularly for non-productive, dry cough. Research suggests that noscapine's activity is related to its effect on the cough center in the brain, while codeine, an opioid, is also observed to have centrally-acting cough suppressant effects.

However, a review of randomized controlled trials (RCTs) for codeine in the treatment of acute cough in adults indicated a lack of robust evidence to confirm its superiority over a placebo. Similarly, research on noscapine has sometimes yielded conflicting results regarding its effectiveness in controlled human studies using experimentally induced cough.

---

Adverse Events and Comparative Research

A non-interventional, controlled multicenter study examined the tolerability of noscapine versus codeine (or dihydrocodeine) in patients treated for unproductive dry cough. Studies have noted findings related to discontinuation rates and reported adverse events in the adult populations included in that study, suggesting differences in the adverse event profile between the two drug classes.

It is important to note that due to known risks associated with use, national regulatory authorities in many regions do not recommend codeine-based medications for children under 12 years of age for the treatment of cough, citing insufficient evidence of efficacy and concerns over potential adverse events.

Common questions about Makatussin Comp. (FAQ)

---

Q: What is Makatussin Comp. and what is it used for?

Makatussin Comp. is a cough syrup that contains two main active ingredients: codeine and promethazine. It is primarily used to relieve a dry, irritating cough.

• Codeine is an opioid that acts as a cough suppressant (antitussive), working in the brain to reduce the urge to cough.
• Promethazine is an antihistamine that can help relieve allergy symptoms and also has a mild sedative effect.

---

Q: What are the potential side effects of Makatussin Comp.?

Common side effects of Makatussin Comp. may include drowsiness, dizziness, constipation, or nausea. Because of the codeine content, there is also a risk of dependence or addiction with prolonged or high-dose use. Promethazine can cause significant sedation and impaired judgment.

Serious side effects can include severe difficulty breathing (respiratory depression), signs of an allergic reaction (rash, itching, swelling), or signs of serotonin syndrome (agitation, hallucinations, fever).

---

Q: Can I drive or operate machinery while taking Makatussin Comp.?

No, you should not drive or operate heavy machinery while taking Makatussin Comp. The active ingredients, especially promethazine and codeine, cause significant drowsiness, dizziness, and impaired coordination and concentration. These effects can make tasks requiring alertness, such as driving, dangerous. This is a crucial safety precaution.

---

Q: Is it safe to drink alcohol while taking Makatussin Comp.?

No, it is not safe to consume alcohol while taking Makatussin Comp. Both alcohol and the active ingredients in the syrup (codeine and promethazine) are central nervous system (CNS) depressants. Combining them significantly increases the risk of severe side effects, including extreme drowsiness, severe dizziness, slowed breathing (respiratory depression), coma, and potentially death. Avoid alcohol completely while using this medication.

---

Q: How should Makatussin Comp. be stored?

Store Makatussin Comp. at room temperature (typically between 68 F and 77 F or 20 C and 25 C) and away from moisture and heat. Keep the bottle tightly closed when not in use. It is essential to keep this medication out of the reach of children and pets due to the risk of accidental overdose from the opioid component (codeine).

Official Storage and Disposal Requirements

Makatussin Comp. Hustensirup must be stored at room temperature, which is officially defined as the range between 15 C and 25 C. It is mandatory that the medicine is kept strictly out of the sight and reach of children due to the risk associated with accidental ingestion of the opioid component.

Condition	Requirement
Temperature	Store between 15 C and 25 C.
Stability	Use within six months after the bottle is first opened.
Access	Keep out of the sight and reach of children.
Disposal	Unused or expired product must be disposed of properly via official pharmaceutical channels.

Disposal instructions require that any unused or expired syrup is discarded according to pharmaceutical waste regulations, ensuring it is not introduced into household waste or wastewater.